Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 4/20 | 0.56 |
| ▸ | ESR2 known ✓ | Q92731 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | CES2 | O00748 | 4/20 | 0.44 |
| ▸ | CES1 | P23141 | 4/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28563070 | 1.00 | CYP3A4 (0.67) | CYP3A4TDP1ESR1ESR2CES2 | |
| Acetic Acid SCHEMBL28985507 | 1.00 | CYP3A4 (0.67) | CYP3A4TDP1ESR1ESR2CES2 | |
| Acetic Acid SCHEMBL158139 | 1.00 | CYP3A4 (0.67) | CYP3A4TDP1ESR1ESR2CES2 | |
| Acetic Acid SCHEMBL7629010 | 1.00 | CYP3A4 (0.67) | CYP3A4TDP1ESR1ESR2CES2 | |
| Acetic Acid SCHEMBL8050008 | 1.00 | CYP3A4 (0.67) | CYP3A4TDP1ESR1ESR2CES2 | |
| Acetic Acid SCHEMBL1076750 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 | |
| Acetic Acid SCHEMBL3889924 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 | |
| Acetic Acid SCHEMBL8926679 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 | |
| Acetic Acid SCHEMBL9816160 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 | |
| Acetic Acid SCHEMBL8682342 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1260505-B1 | A process for the preparation of 4-[1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-butyl]-alpha, alpha-dimethylbenzeneacetic acid | DIPHARMA SPA (IT) | 2005-03-09 | — | — | EP | claimed |
| US-6815549-B2 | REACTING AN ACETYLINIC COMPOUND CONTAINING HALOGEN OR SULFONATE GROUP WITH A 4-((4-HYDROXYDIPHENYLMETHYL)-1-PIPERIDINE) TO FORM ANINTERMEDIATE, CONDENSING IT WITH AN DIMETHYLBENZENE ACETATES | DINAMITE DIPHARMA S.P.A. (IT) | 2004-11-09 | — | — | US | claimed |
| US-20020198233-A1 | Process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethly)-1-piperidinyl]-butyl]-alpha,alpha-dimethylbenzeneacetic acid | DINAMITE DIPHARMA S.P.A. ABBREVIATED DIPHARMA S.P.A. (IT) | 2002-12-26 | — | — | US | claimed |
| EP-1260505-A1 | A process for the preparation of 4-[1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-butyl]-alpha, alpha-dimethylbenzeneacetic acid | Dinamite Dipharma S.p.A. (IT) | 2002-11-27 | — | — | EP | claimed |
| WO-1998024747-A1 | A PROCESS FOR THE PREPARATION OF NABUMETONE | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1998-06-11 | — | — | WO | claimed |
| EP-0329021-B1 | Preparation of advanced epoxy resins and dihydric phenols in the presence of phosphonium compounds | DOW CHEMICAL CO (US) | 1994-01-26 | — | — | EP | claimed |
| EP-0329021-A2 | Preparation of advanced epoxy resins and dihydric phenols in the presence of phosphonium compounds | THE DOW CHEMICAL COMPANY (US) | 1989-08-23 | — | — | EP | claimed |
| CN-117295752-A | Monomers, polymerizable compositions, and polymers derived therefrom | 3M创新有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-116948060-A | Method for hydrogenation of nitrile rubber by single ruthenium catalyst | 西安凯立新材料股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-107922555-A | Curing composition | 东亚合成株式会社 | 2018-04-17 | — | — | CN | disclosed |
| CN-101448870-A | Powder coating compositions containing highly functional, highly branched or hyperbranched polycarbonates | BASF COATINGS AG (DE) | 2009-06-03 | — | — | CN | disclosed |
| CN-100491445-C | Powder coating matting agents comprising esteramide condensation products | GRACE GMBH & CO KG (DE) | 2009-05-27 | — | — | CN | disclosed |
| CN-1671771-A | Powder coating matting agent comprising ester amide condensation product | GRACE GMBH & CO KG (DE) | 2005-09-21 | — | — | CN | disclosed |
| EP-0209572-A4 | EPOXY NOVOLAC RESINS HAVING REDUCED 2-FUNCTIONAL COMPONENTS AND A PROCESS FOR REDUCING 2-FUNCTIONAL COMPONENTS IN NOVOLAC RESINS. | DOW CHEMICAL CO (US) | 1988-10-24 | — | — | EP | disclosed |
| CN-87104910-A | Cationic improved epoxy resin compositions | — | 1988-05-04 | — | — | CN | disclosed |
| WO-1988000604-A1 | CONTROLLED FILM BUILD CATHODIC ELECTRODEPOSITION EPOXY COATINGS | THE DOW CHEMICAL COMPANY (US) | 1988-01-28 | — | — | WO | disclosed |
| EP-0253404-A2 | Controlled film build epoxy coatings applied by cathodic electrodeposition | THE DOW CHEMICAL COMPANY (US) | 1988-01-20 | — | — | EP | disclosed |
| US-4708996-A | Stable dispersions of polymers in polyepoxides | THE DOW CHEMICAL COMPANY (US) | 1987-11-24 | — | — | US | disclosed |
| EP-0209572-A1 | EPOXY NOVOLAC RESINS HAVING REDUCED 2-FUNCTIONAL COMPONENTS AND A PROCESS FOR REDUCING 2-FUNCTIONAL COMPONENTS IN NOVOLAC RESINS | THE DOW CHEMICAL COMPANY (US) | 1987-01-28 | — | — | EP | disclosed |
| WO-1986004075-A1 | EPOXY NOVOLAC RESINS HAVING REDUCED 2-FUNCTIONAL COMPONENTS AND A PROCESS FOR REDUCING 2-FUNCTIONAL COMPONENTS IN NOVOLAC RESINS | THE DOW CHEMICAL COMPANY (US) | 1986-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198233-A1 | Process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethly)-1-piperidinyl]-butyl]-alpha,alpha-dimethylbenzeneacetic acid | P4HA1, CYP4X1, HRH2 | ESR1 4018/4885ESR2 2968/4885CYP3A4 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.